RxDoctor Payments Data

Dunia Llapur Hernandez

Internal Medicine · Miami, FLNPI 1285052043

Payments from drug & device makers

What this record shows

5 manufacturers reported payments, led by Eli Lilly at 51.7% of the total. 2024 is the largest year on record at $1,518, more than ten times the $54 reported in 2019.

$1,606in general payments, 2019–2025

Across 15 payments — averaging $107.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$830
  • Pfizer$699
  • Novo Nordisk$39
  • Boehringer Ingelheim$22
  • Bayer$17
$4,397,286in research payments, 2019–2025

Across 364 payments — averaging $12,080 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$1.8M
  • Boehringer Ingelheim$898K
  • Pfizer$615K
  • AbbVie$564K
  • Amgen$266K
  • Vanda Pharmaceuticals Inc.$109K
  • plus $148K from 3 others

What the payments were for

  • Travel & lodging$91257%
  • Food & beverage$69443%

General payments by program year

19
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly7$830
Pfizer4$699
Novo Nordisk2$39
Boehringer Ingelheim1$22
Bayer1$17

How this compares

$1,606 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →